Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook

MUMBAI - The first tangible benefits of the deal Dr. Reddy's Labs struck last year with GlaxoSmithKline for supply of over 100 branded formulations have become visible with the Indian company receiving $4 million from its British partner in return for moving dossiers and trademarks for nine currently marketed products in Brazil